Who owns MAP Pharmaceuticals?

Key details on MAP Pharmaceuticals (Ticker: MAPP)

Who owns MAP Pharmaceuticals?

Is MAPP a good stock to own? Find out who bought MAP Pharmaceuticals, who sold MAP Pharmaceuticals (MAPP) stock, and who holds a large position in MAP Pharmaceuticals.

Fund Name Number of Shares Share Valuation As Of
Jennison Associates 3.90M $61.32M Dec. 31, 2012
Brookside Capital Management, LLC* 3.00M $46.94M Dec. 31, 2012
OrbiMed Advisors 2.83M $44.27M Dec. 31, 2012
T. Rowe Price Associates 2.42M $37.96M Dec. 31, 2012
OppenheimerFunds 1.91M $29.96M Dec. 31, 2012
Vanguard 1.49M $23.47M Dec. 31, 2012
Oracle Investment Management 1.09M $17.08M Dec. 31, 2012
ALLIANCEBERNSTEIN 997514 $15.67M Dec. 31, 2012
Ameriprise Financial 909020 $13.62M June 30, 2012
Wellington Management Company 638562 $10.03M Dec. 31, 2012
STATE STREET CORPORATION 610087 $9.58M Dec. 31, 2012
Deerfield Management Company 583439 $9.13M Dec. 31, 2012
TCW 574598 $9.03M Dec. 31, 2012
Oxford Asset Management 496081 $7.12M March 31, 2012
Inves 462020 $7.19M Sept. 30, 2012
CITADEL ADVISORS 420544 $6.61M Dec. 31, 2012
Stephens Investment Management 408565 $6.42M Dec. 31, 2012
Barclays 399100 $5.73M March 31, 2012
Bridger Management 378134 $4.98M Dec. 31, 2011
Adage Capital Partners GP 358794 $4.73M Dec. 31, 2011
Thomas Weisel Asset Management 346157 $5.42M Dec. 31, 2012

Who sold MAP Pharmaceuticals?

Fund Name Date Sold Number of Shares Sold Share Valuation
Palisade Capital Management Dec. 31, 2012 687090 $10.75M
Soros Fund Management March 31, 2011 1.05M $14.47M
Bank of America Corporation March 31, 2011 487090 $6.72M
FMR Dec. 31, 2010 4.52M $75.65M
Diamondback Capital Management Sept. 30, 2009 438046 $4.58M